Development of Neuropathic Post-COVID Pain Symptoms Is Not Associated with Serological Biomarkers at Hospital Admission in COVID-19 Survivors: A Secondary Analysis

Pain Med. 2022 Dec 1;23(12):2092-2094. doi: 10.1093/pm/pnac086.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • COVID-19* / complications
  • Hospitals
  • Humans
  • Neuralgia* / etiology
  • Survivors

Substances

  • Biomarkers